Philadelphia Group Confirms GenoMed's Approach to Pancreatic Cancer
GenoMed(TM) (Pink Sheets:GMED), the Next Generation Disease Management company whose business is public health(TM), announced today that its published approach to cancer has recently received support from a group at Thomas Jefferson University in Philadelphia.
Dr. Hwyda Arafat at the Kimmel Cancer Center at Thomas Jefferson University recently showed that angiotensin I-converting enzyme (ACE) was active in tumors from patients with pancreatic cancer, and that ACE inhibitors and angiotensin II receptor blockers (ARBs) blocked the production of a potent angiogenesis factor called VEGF in pancreatic cancer cell lines. She suggested that ACE inhibitors and ARBs might be useful in treating pancreatic cancer patients.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our work, published four years ago, demonstrated that ACE inhibitors and ARBs may work against all but a few cancers. In fact, two years ago we published a case report of a woman with stage IV unresectable pancreatic cancer who lived an extra 14 months using our approach."
Added Dr. Moskowitz, "We're delighted for others to confirm our work again, but if people with cancer, sickle cell disease, viral disease, high blood pressure, diabetes, kidney failure, or emphysema only knew about us, we might be able to help save their lives. At this point, as with the rest of our treatments, the only element missing is public awareness."
About GenoMed
GenoMed owns "use" patents (which are pending) for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure. GenoMed estimates that it can already save 10% of healthcare costs and extend life by several years. The company is currently trying to publicize its intellectual property, since having cures is useless if nobody knows about them. |
